4.6 Editorial Material

Special cells, special considerations: The challenges of bringing embryonic stem cells from the laboratory to the clinic

期刊

CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 83, 期 3, 页码 386-389

出版社

WILEY
DOI: 10.1038/sj.clpt.6100384

关键词

-

资金

  1. NIBIB NIH HHS [R21 EB005252, R21 EB005252-03, EB005252, R21 EB005252-02] Funding Source: Medline
  2. NINDS NIH HHS [R01 NS045062, R01 NS045062-03, NS045062, R01 NS045062-04] Funding Source: Medline
  3. NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R21EB005252] Funding Source: NIH RePORTER
  4. NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045062] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Human embryonic stem (ES) cells are an attractive tool for cell-based therapies because of their limitless capacity for proliferation and their ability to differentiate into all cell types of the body. However, these features introduce certain unique risks that must be considered in developing transplantation strategies for clinical use. We outline these risks and examine current approaches to address them, both before and after transplantation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据